Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

doi:10.1038/nm.1890

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Nature medicine - 1 Dec 2008

Engelman Jeffrey A, Chen Liang, Tan Xiaohong, Crosby Katherine, Guimaraes Alexander R, Upadhyay Rabi, Maira Michel, McNamara Kate, Perera Samanthi A, Song Youngchul, Chirieac Lucian R, Kaur Ramneet, Lightbown Angela, Simendinger Jessica, Li Timothy, Padera Robert F, García-Echeverría Carlos, Weissleder Ralph, Mahmood Umar, Cantley Lewis C, Wong Kwok-Kin

Abstract excerpt

Somatic mutations that activate phosphoinositide 3-kinase (PI3K) have been identified in the p110-alpha catalytic subunit (encoded by PIK3CA). They are most frequently observed in two hotspots: the helical domain (E545K and E542K) and the kinase domain (H1047R). Although the p110-alpha mutants are transforming in vitro, their oncogenic potential has not been assessed in genetically engineered mouse models....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down-Regulation

Share to Gene Expression Regulation, Neoplastic

Share to MAP Kinase Signaling System

Share to Mitogen-Activated Protein Kinase Kinases

Share to Phosphatidylinositol 3-Kinases

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 19029981
DOI: 10.1038/nm.1890
PMCID: PMC2683415

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.PMID 19029981Read ↗

Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.Semantic proximity Read ↗

Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.Semantic proximity Read ↗

Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047RSemantic proximity Read ↗

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.Semantic proximity Read ↗

PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung TumorigenesisSemantic proximity Read ↗

Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade.Semantic proximity Read ↗

Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.Semantic proximity Read ↗

Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.Semantic proximity Read ↗

Cancer-specific mutations in PIK3CA are oncogenic in vivo.Semantic proximity Read ↗

Loss of PIK3CA Allows In Vitro Growth but Not In Vivo Progression of KRAS Mutant Lung Adenocarcinoma in a Syngeneic Orthotopic Implantation Model.Semantic proximity Read ↗

Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations In vivoSemantic proximity Read ↗

Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.